Skip to main content
. 2014 Sep 23;7:1689–1704. doi: 10.2147/OTT.S66502

Figure 2.

Figure 2

Schematic summary of measures to overcome tumor heterogeneity and drug resistance in lung cancer.

Notes: Spatial heterogeneity indicates inter-/intratumor differences at the genomic, epigenetic, and proteomic levels, whereas temporal heterogeneity reflects dynamic tumor evolution over time. Some diagnostic and therapeutic approaches have been validated in patients for clinical translation.

Abbreviation: TKI, tyrosine kinase inhibitors.